What is the official ID of this bill?

The official print number for this legislation is HR 2884.

When did the legislative process begin?

The process officially started on 2021-04-28.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/117/bills/hr2884/BILLS-117hr2884ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

Who is the primary sponsor?

The primary sponsor is Rep. Johnson, Henry C. "Hank," Jr. [D-GA-4].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Ordered to be Reported in the Nature of a Substitute by Voice Vote.

Analysis and Potential Impact of HR 2884

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Cheaper Medicines: Patent Dispute Changes for Biologic Products.

Q: What are the main provisions?

Key points include: Limits the number of patents that can be asserted in legal disputes over biologic drugs, aiming to accelerate the introduction of cheaper alternatives. Allows for an increase in the number of patents in a dispute only under specific justified circumstances, such as when a generic company fails to provide required information. These provisions apply to applications for biologic drug approval submitted after the act's enactment, impacting future medications.

New rules aim to simplify the market entry of more affordable versions of biologic drugs, potentially lowering their prices. The act limits the number of patents pharmaceutical companies can use in legal disputes, speeding up access to generic equivalents. This could mean easier access to necessary medications and potentially lower healthcare costs for citizens.

Key points

Limits the number of patents that can be asserted in legal disputes over biologic drugs, aiming to accelerate the introduction of cheaper alternatives.

Allows for an increase in the number of patents in a dispute only under specific justified circumstances, such as when a generic company fails to provide required information.

These provisions apply to applications for biologic drug approval submitted after the act's enactment, impacting future medications.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act

Print number: HR 2884

Sponsor: Rep. Johnson, Henry C. "Hank," Jr. [D-GA-4]

Process start date: 2021-04-28

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-05-20

Source data: api.congress.gov

AI work logs for this document launch

Cheaper Medicines: Patent Dispute Changes for Biologic Products.

Key Questions about Cheaper Medicines: Patent Dispute Changes for Biologic Products.